Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - July 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2016. This month there are seven clinical guidelines and two technology appraisals that impact upon primary care.

The Type 2 diabetes in adults clinical guideline has been updated to clarify the role of GPs in referring people for eye screening and also to add information on when this should happen.

The Type 1 diabetes in adults clinical guideline has also been updated to clarify the role of GPs in referring people for eye screening and also to add information on when this should happen.

The Non-Hodgkin’s lymphoma clinical guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes.

The Cardiovascular disease: risk assessment and reduction guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease. It describes the lifestyle changes people can make and how statins can be used to reduce their risk. It has been updated to clarify the advice on saturated and monounsaturated fat.

The Prophylaxis against infective endocarditis guideline has been updated to make the wording of two of the recommendations more consistent.

The Non-alcoholic fatty liver disease guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

The Oral health for adults in care homes guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.

The Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy technology appraisal has been reviewed after a change to the commercial arrangements in July 2016. It has been verified that this change does not impact cost effectiveness and supply is contingent upon the manufacturer providing abiraterone in accordance with the commercial access arrangement as agreed with NHS England.

The Abiraterone for castration-resistant metastatic prostate cancer technology appraisal has been reviewed after a change to the commercial arrangements in July 2016. It has been verified that this change does not impact cost effectiveness and supply is contingent upon the manufacturer providing abiraterone in accordance with the commercial access arrangement as agreed with NHS England.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - July 2016' on Email Share 'NICE Guidance - July 2016' on Delicious Share 'NICE Guidance - July 2016' on Digg Share 'NICE Guidance - July 2016' on Facebook Share 'NICE Guidance - July 2016' on Google+ Share 'NICE Guidance - July 2016' on reddit Share 'NICE Guidance - July 2016' on StumbleUpon Share 'NICE Guidance - July 2016' on Twitter

atomic-wealth

No Comments to “NICE Guidance - July 2016”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,083 spam comments.

atomic-wealth
fond-illness
summer